NEW YORK (360Dx) – Vermillion reported after the close of the market on Thursday a 12 percent year-over-year jump in its third quarter revenues.

For the three months ended Sept. 30, the Austin, Texas-based cancer diagnostics firm said that total revenues rose to $774,000 from $699,000 in the year-ago quarter.

Product revenues were $739,000, up 12 percent from $657,000 in Q3 2017. Service revenues from the company's Aspira IVD business were down 17 percent to $35,000 from $42,000 in Q3 2017.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.


In this webinar, Dr. Wendy Béguelin of Weill Cornell Medicine will discuss how she used the BD Rhapsody single-cell RNA-seq platform and YFP floxed reporter mouse models to study how lymphoma-associated mutations disrupt the immune system by affecting GC B-cell states, explaining the biology of initiation of low-grade follicular lymphoma.